Unmet Medical Needs in Metastatic Lung and Digestive Neuroendocrine Neoplasms

被引：7

作者：

Capdevila, Jaume ^{[1
]}

Bodei, Lisa ^{[2
]}

Davies, Philippa ^{[3
]}

Gorbounova, Vera ^{[4
]}

Jensen, Robert T. ^{[5
]}

Knigge, Ulrich P. ^{[6
]}

Krejs, Guenter J. ^{[7
]}

Krenning, Eric ^{[8
]}

O'Connor, Juan Manuel ^{[9
]}

Peeters, Marc ^{[10
]}

Rindi, Guido ^{[11
]}

Salazar, Ramon ^{[12
]}

Vullierme, Marie-Pierre ^{[13
]}

Pavel, Marianne E. ^{[14
]}

Arnold, R. ^{[15
]}

Bartsch, D. ^{[16
]}

Baudin, E. ^{[17
]}

Bodei, L. ^{[2
]}

Borbath, I ^{[18
]}

Capdevila, J. ^{[19
]}

Caplin, M. ^{[20
]}

Chen, J. ^{[21
]}

Costa, F. ^{[22
]}

Couvelard, A. ^{[23
]}

Cwikla, J. B. ^{[24
]}

Davies, P. ^{[25
]}

de Herder, W. W. ^{[26
]}

Falconi, M. ^{[27
]}

Falkerby, J. ^{[28
]}

Fazio, N. ^{[29
]}

Ferone, D. ^{[30
]}

Frilling, A. ^{[31
]}

Garcia-Carbonero, R. ^{[32
]}

Glasberg, S. ^{[33
]}

Gorbunova, V ^{[34
]}

Grossman, A. ^{[35
]}

Hoersch, D. ^{[36
]}

Jensen, R. T. ^{[5
]}

Kaltsas, G. ^{[37
]}

Kloeppel, G. ^{[38
]}

Knigge, U. P. ^{[39
]}

Kos-Kudla, B. ^{[40
]}

Krejs, G. J. ^{[41
]}

Krenning, E. ^{[42
]}

Kulke, M. ^{[43
]}

Lamberts, S. W. J.

van Dijkum, Nieveen E. ^{[44
]}

O'Connor, J. M. ^{[45
]}

O'Toole, D. ^{[46
,47
]}

Pape, U. F. ^{[48
]}

机构：

[1] Vall Hebron Univ Hosp, VHIO, Barcelona, Spain

[2] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA

[3] Royal Free Hosp, Neuroendocrine Tumour Unit, London, England

[4] Inst Russian Acad Med Sci, Dept Oncol, Moscow, Russia

[5] NIH, Bldg 10, Bethesda, MD 20892 USA

[6] Univ Copenhagen, Dept Surg, Copenhagen, Denmark

[7] Med Univ Graz, Graz, Austria

[8] Erasmus MC, Cyclotron Rotterdam BV, Rotterdam, Netherlands

[9] Alexander Fleming Inst, Caba, Argentina

[10] Antwerp Univ Hosp, Dept Oncol, Antwerp, Belgium

[11] Univ Cattolica Sacro Cuore, Fdn Policlin Univ A Gemelli IRCCS Roma, Rome, Italy

[12] Catalan Inst Oncol, Oncobell Program, IDIBELL, Cerca,Ciberonc, Barcelona, Spain

[13] Beaujon Hop Assistance Publ, Radiol Dept, Paris, France

[14] Friedrich Alexander Univ Erlangen Nurnberg, Univ Klinikum Erlangen, Erlangen, Germany

[15] Univ Hosp, Marburg, Germany

[16] UKGM GmbH, Marburg, Germany

[17] Inst Gustave Roussy, Villejuif, France

[18] Clin Univ, St Luc, Belgium

[19] Vall dHebron Univ Hosp, VHIO, Barcelona, Spain

[20] Royal Free Hosp, Dept Med, London, England

[21] Sun Yat Sen Univ, Affiliated Hosp 1, Guangzhou, Guangdong, Peoples R China

[22] Care Of Frederico Costa, Oncoclin Med Associados S S Ltda, Lima, Brazil

[23] Hop Bichat Claude Bernard, Serv Pathol, Paris, France

[24] Univ Warmia & Mazury, Fac Med Sci, Dept Radiol, Olsztyn, Poland

[25] Royal Free Hosp, Neuroendocrine Tumour Unit, London, England

[26] Erasmus MC, Dept Internal Med, Sect Endocrinol, Rotterdam, Netherlands

[27] Univ Vita & Salute, Dept Surg, Milan, Italy

[28] Dept Endocrine Oncol, Uppsala, Sweden

[29] European Inst Oncol, Milan, Italy

[30] Univ Genoa, Genoa, Italy

[31] Imperial Coll London, Hammersmith Hosp, Dept Surg & Canc, London, England

[32] Hosp Univ Doce Octubre, Madrid, Spain

[33] Hadassah Univ, Jerusalem, Israel

[34] Univ Rochester, Rochester, NY USA

[35] Royal Free Hosp, London, England

[36] Zent Klin Bad Berka GmbH, CA Gastroenterol, Bad Berka, Germany

[37] Natl Univ Athens, Dept Pathophysiol, Endocrine Unit, Athens, Greece

[38] Tech Univ Munich, Dept Pathol, Consultat Ctr Pancreat & Endocrine Tumors, Munich, Germany

[39] Univ Copenhagen, Rigshosp, Dept Surg C2122, Copenhagen, Denmark

[40] Med Univ Silesia, Dept Endocrinol & Neuroendocrine Tumors, Katowice, Poland

[41] Med Univ Graz, Graz, Austria

[42] Erasmus MC, Dept Nucl Med, Rotterdam, Netherlands

[43] Dana Farber Canc Inst, Boston, MA 02115 USA

[44] Amsterdam Working Hosp, Amsterdam, Netherlands

[45] Alexander Fleming Inst, Caba, Argentina

[46] St Jamess & St Vincents Univ Hosp, Dublin, Ireland

[47] Trinity Coll Dublin, Dublin, Ireland

[48] Charite Campus Mitte, Berlin, Germany

[49] Univ Vita Salute San Raffaele, San Raffaele Sci Inst, Pancreas Translat & Clin Res Ctr, Pancreat Surg Unit, Milan, Italy

[50] Antwerp Univ Hosp, Dept Oncol, Antwerp, Belgium

来源：

NEUROENDOCRINOLOGY | 2019年 / 108卷 / 01期

关键词：

Unmet medical needs; Neuroendocrine neoplasms; Metastasis; Biomarkers; Imaging; Therapy; TUMORS; SUNITINIB; LANREOTIDE; EVEROLIMUS; SURVIVAL;

D O I：

10.1159/000493319

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Unmet medical needs are not infrequent in oncology, and these needs are usually of higher magnitude in rare cancers. The field of neuroendocrine neoplasms (NENs) has evolved rapidly during the last decade, and, currently, a new WHO classification is being implemented and several treatment options are available in the metastatic setting after the results of prospective phase III clinical trials. However, several questions are still unanswered, and decisions in our daily clinical practice should be made with limited evidence. In the 2016 meeting of the advisory board of the European Neuroendocrine Tumor Society (ENETS), the main unmet medical needs in the metastatic NENs setting were deeply discussed, and several proposals to try to solve them are presented in this article, including biomarkers, imaging, and therapy.

引用

页码：18 / 25

页数：8

共 22 条

[1]

[Anonymous], 2016, CLIN ADV HEMATOL ONC, V14, P6

[2] 18F-Fluorodeoxyglucose Positron Emission Tomography Predicts Survival of Patients with Neuroendocrine Tumors [J].

Binderup, Tina ;

Knigge, Ulrich ;

Loft, Annika ;

Federspiel, Birgitte ;

Kjaer, Andreas .

CLINICAL CANCER RESEARCH, 2010, 16 (03) :978-985

[3] Evaluation of the efficacy and safety of lanreotide in combination with targeted therapies in patients with neuroendocrine tumours in clinical practice: a retrospective cross-sectional analysis [J].

Capdevila, Jaume ;

Sevilla, Isabel ;

Alonso, Vicente ;

Anton Aparicio, Luis ;

Jimenez Fonseca, Paula ;

Grande, Enrique ;

Jose Reina, Juan ;

Luis Manzano, Jose ;

Alonso Lajara, Juan Domingo ;

Barriuso, Jorge ;

Castellano, Daniel ;

Medina, Javier ;

Lopez, Carlos ;

Segura, Angel ;

Carrera, Sergio ;

Crespo, Guillermo ;

Fuster, Jose ;

Munarriz, Javier ;

Garcia Alfonso, Pilar .

BMC CANCER, 2015, 15

[4] Exploratory analysis of tumor growth rate (TGR) with lanreotide depot/autogel (LAN) in patients (pts) with neuroendocrine tumors (NETs) from the CLARINET study [J].

Caplin, Martyn E. ;

Pavel, Marianne E. ;

Ruszniewski, Philippe ;

Liyanage, Nilani ;

Massien, Christine ;

Dromain, Clarisse .

JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)

[5] Anti-tumour effects of lanreotide for pancreatic and intestinal neuroendocrine tumours: the CLARINET open-label extension study [J].

Caplin, Martyn E. ;

Pavel, Marianne ;

Cwikla, Jaroslaw B. ;

Phan, Alexandria T. ;

Raderer, Markus ;

Sedlackova, Eva ;

Cadiot, Guillaume ;

Wolin, Edward M. ;

Capdevila, Jaume ;

Wall, Lucy ;

Rindi, Guido ;

Langley, Alison ;

Martinez, Severine ;

Gomez-Panzani, Edda ;

Ruszniewski, Philippe .

[6] Imaging response in neuroendocrine tumors treated with targeted therapies: the experience of sunitinib [J].

Faivre, Sandrine ;

Ronot, Maxime ;

Dreyer, Chantal ;

Serrate, Camille ;

Hentic, Olivia ;

Bouattour, Mohamed ;

Bruno, Onorina ;

Couvelard, Anne ;

Vilgrain, Valerie ;

Raymond, Eric .

TARGETED ONCOLOGY, 2012, 7 (02) :127-133

[7] Tumor Growth Rate Is an Early Indicator of Antitumor Drug Activity in Phase I Clinical Trials [J].

Ferte, Charles ;

Fernandez, Marianna ;

Hollebecque, Antoine ;

Koscielny, Serge ;

Levy, Antonin ;

Massard, Christophe ;

Balheda, Rastislav ;

Bot, Brian ;

Gomez-Roca, Carlos ;

Dromain, Clarisse ;

Ammari, Samy ;

Soria, Jean-Charles .

CLINICAL CANCER RESEARCH, 2014, 20 (01) :246-252

[8]

Ilie M, 2014, ANN TRANSL MED, V2, DOI 10.3978/j.issn.2305-5839.2014.08.11

[9] Circulating Tumor Cells As Prognostic Markers in Neuroendocrine Tumors [J].

Khan, Mohid S. ;

Kirkwood, Amy ;

Tsigani, Theodora ;

Garcia-Hernandez, Jorge ;

Hartley, John A. ;

Caplin, Martyn E. ;

Meyer, Tim .

JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (03) :365-372

[10] A randomized, open-label, phase 2 study of everolimus in combination with pasireotide LAR or everolimus alone in advanced, well-differentiated, progressive pancreatic neuroendocrine tumors: COOPERATE-2 trial [J].

Kulke, M. H. ;

Ruszniewski, P. ;

Van Cutsem, E. ;

Lombard-Bohas, C. ;

Valle, J. W. ;

De Herder, W. W. ;

Pavel, M. ;

Degtyarev, E. ;

Brase, J. C. ;

Bubuteishvili-Pacaud, L. ;

Voi, M. ;

Salazar, R. ;

Borbath, I. ;

Fazio, N. ;

Smith, D. ;

Capdevila, J. ;

Riechelmann, R. P. ;

Yao, J. C. .

ANNALS OF ONCOLOGY, 2017, 28 (06) :1309-1315

← 1 2 3 →